Ginkgo Bioworks Holdings, Inc.
Could not find a ticker for this position, may be a filing error
A maker of cell-engineering tools, Ginkgo Bioworks designs custom organisms and cells for pharmaceutical, agricultural, and industrial clients, using lab automation and AI models. Its Canopy and Horizon biosecurity platforms monitor wastewater and other samples for government customers to spot emerging biological threats. Founded in 2008 by five MIT scientists who wanted to make biology easier to engineer, the company took its name from the ginkgo tree, an ancient "living fossil" unchanged for tens of millions of years.
Warrant (expires 08/01/202)
Granted 307.3K · Sold 151.0K
Granted 307.3K · Sold 151.0K
Granted 425.9K · Sold 206.8K
Granted 76.9K · Sold 34.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Canton Barry10% owner · 6 transactions | -96.9% | 775.0K | 307.3K | — | 151.0K |
| Shetty Reshma P.See remarks, Director, 10% owner · 6 transactions | -96.9% | 775.0K | 307.3K | — | 151.0K |
| Kelly Jason RSee remarks, Director · 4 transactions | -91.9% | 316.5K | 425.9K | — | 206.8K |
| Coen Steven P.See remarks · 12 transactions | +509.3% | 50.7K | 76.9K | — | 34.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -543.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.